The NHS has unveiled an innovative tech initiative to help people who are most at risk of developing type 2 diabetes. According to Pharma File on Wednesday, the news coincided with World Diabetes Day, which was on Tuesday.
The novel scheme will see more than 5,000 patients in eight areas of England enrolled. They will each be tested and monitored using apps that track physical activity and other health data.
Five companies will provide their devices for the trial; these include wristbands that provide feedback to mobile devices and a six-week mobile and desktop digital programme that measures sleep and helps with healthy eating. Researchers hope to establish whether digital interventions like these can offer a cost effective means of preventing high-risk patients from developing type 2 diabetes.
Duncan Selbie, chief executive at Public Health England, commented: "This breaks new ground to help those at risk of type 2 diabetes quite literally take their health into their own hands. Many of us use on-the-go digital technology every day and this is a logical next step in diabetes prevention."
Simon Stevens, the CEO of NHS England, added: "So much else in our lives is now about online social connection and support, and that now needs to be true too for the modern NHS. This is the latest example of how the NHS is getting practical and serious about supporting people to stay healthy".
Galderma secures EU MDR certification for Sculptra, expanding use to multiple body areas
Clinical Laserthermia Systems applies for CE marking of ClearPoint Prism neuro laser system
Bonesupport shifts CERAMENT V review to FDA's De Novo pathway
Neola Medical secures US patent for disposable lung monitoring probes
Remington Medical's VascuChek 2.0 Cordless Bluetooth-Enabled Doppler Secures FDA Clearance
Aetna to launch generative AI-powered conversational experience
Maxx Orthopedics Receives FDA 510(k) Clearance for Its Libertas® Bipolar Hip System
Ascletis Pharma announces ASC36 and ASC35 co-formulation for clinical development
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies
Nurami Medical completes Phase 1 milestones in EIC-backed grant for Artifix